Rapanelli, Maximiliano
Wang, Wei
Hurley, Edward
Feltri, Maria Laura
Pittenger, Christopher http://orcid.org/0000-0003-2117-9321
Frick, Luciana Romina http://orcid.org/0000-0001-5595-8636
Yan, Zhen http://orcid.org/0000-0002-3519-9596
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2TR001413)
Brain and Behavior Research Foundation (24910)
Nancy Lurie Marks Family Foundation
Article History
Received: 30 November 2022
Revised: 2 January 2023
Accepted: 6 January 2023
First Online: 24 January 2023
Competing interests
: CP consults and/or receives research funding from Biohaven Pharmaceuticals, Transcend Therapeutics, Freedom Biosciences, Ceruvia Lifesciences, and Nobilis Therapeutics and receives royalties from Oxford University Press. He has filed patents on the use of psilocybin and of neurofeedback in the treatment of obsessive-compulsive disorder that are not relevant to this work. MR, WW, EH, MLF, LRF, and ZY report no biomedical financial interests or potential conflicts of interest.